Ratings Microbix Biosystems Inc.

Equities

MBX

CA59501P1045

Market Closed - Toronto S.E. Other stock markets 11:34:48 21/06/2024 pm IST			5-day change	1st Jan Change
0.335 ^CAD	0.00%		+3.08%	-14.10%

17/06	Microbix Biosystems Inc. Celebrates Opening of Two Expansions to Its Medical Devices Manufacturing Capacity At One of Its Three Adjacent Mississauga Sites	CI
04/06	Microbix Advancing Test-Ingredient Manufacturing Capabilities	MT

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MICROBIX BIOSYSTEMS INC.	-14.10%	33.42M	-	-
MODERNA, INC.	+34.14%	51.12B		B-
IQVIA HOLDINGS INC.	-6.54%	39.4B		B
LONZA GROUP AG	+34.92%	38.48B		A
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B		B-
CELLTRION, INC.	-12.11%	26.22B		C
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B		B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B		B+
MEDPACE HOLDINGS, INC.	+31.81%	12.49B		C+
BIO-TECHNE CORPORATION	-4.54%	11.61B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes